Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.The New England journal of medicine, 355 23
A. Han, E. Chen, G. Niedt, W. Sherman, D. Ratner (2009)
Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.Archives of dermatology, 145 7
D. Kerob, R. Porcher, O. Vérola, S. Dalle, E. Maubec, F. Aubin, M. D’Incan, I. Bodokh, S. Boulinguez, I. Madelaine-Chambrin, A. Mathieu-Boué, J. Servant, E. Kerviler, A. Janin, F. Calvo, F. Pedeutour, C. Lebbé (2010)
Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 PatientsClinical Cancer Research, 16
M. Pretel-Irazabal, A. Tuneu‐Valls, N. Ormaechea‐Pérez (2014)
Adverse skin effects of imatinib, a tyrosine kinase inhibitor.Actas dermo-sifiliograficas, 105 7
Kathryn Kreicher, David Kurlander, H. Gittleman, J. Barnholtz-Sloan, J. Bordeaux (2016)
Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United StatesDermatologic Surgery, 42
Bowne (2000)
Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution.Cancer, 88
M. Tazzari, V. Indio, B. Vergani, L. Cecco, F. Rini, T. Negri, C. Camisaschi, M. Fiore, S. Stacchiotti, G. Dagrada, P. Casali, A. Gronchi, A. Astolfi, M. Pantaleo, A. Villa, C. Lombardo, F. Arienti, S. Pilotti, L. Rivoltini, C. Castelli (2017)
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.The Journal of investigative dermatology, 137 2
K. Thway, J. Noujaim, Robin Jones, C. Fisher (2016)
Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies.Annals of diagnostic pathology, 25
Chunmeng Wang, Zhiguo Luo, Jie Chen, B. Zheng, Ruming Zhang, Yong Chen, Ying-qiang Shi (2015)
Target Therapy of Unresectable or Metastatic Dermatofibrosarcoma Protuberans With Imatinib MesylateMedicine, 94
R. Fields, M. Hameed, L. Qin, N. Moraco, X. Jia, R. Maki, S. Singer, M. Brennan (2011)
Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic TherapyAnnals of Surgical Oncology, 18
M. Heinrich, H. Joensuu, G. Demetri, C. Corless, J. Apperley, J. Fletcher, D. Soulières, S. Dirnhofer, Amy Harlow, Ajia Town, A. McKinley, S. Supple, J. Seymour, Lilla Scala, A. Oosterom, R. Herrmann, Z. Nikolova, And McArthur (2008)
Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine KinasesClinical Cancer Research, 14
P. Rutkowski, M. Debiec-Rychter (2015)
Current treatment options for dermatofibrosarcoma protuberansExpert Review of Anticancer Therapy, 15
A. Oosterom, I. Judson, J. Verweij, S. Stroobants, E. Paola, S. Dimitrijević, M. Martens, A. Webb, R. Sciot, M. Glabbeke, S. Silberman, O. Nielsen (2001)
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 358
N. Fontecilla, N. Kittler, L. Geskin, F. Samie, G. Niedt, T. Imahiyerobo, G. Schwartz, M. Ingham, J. Lewin (2017)
Recurrent dermatofibrosarcoma protuberans treated with neoadjuvant imatinib mesylate followed by Mohs micrographic surgeryJAAD Case Reports, 3
M. Criscito, K. Martires, J. Stein (2016)
Prognostic Factors, Treatment, and Survival in Dermatofibrosarcoma Protuberans.JAMA dermatology, 152 12
S. Ugurel, T. Mentzel, J. Utikal, P. Helmbold, P. Mohr, C. Pföhler, M. Schiller, A. Hauschild, R. Hein, E. Kämpgen, I. Kellner, M. Leverkus, J. Becker, P. Ströbel, D. Schadendorf (2013)
Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-upClinical Cancer Research, 20
J. Verweij, P. Casali, J. Zalcberg, A. Lecesne, P. Reichardt, J. Blay, R. Issels, A. Oosterom, P. Hogendoorn, M. Glabbeke, R. Bertulli, I. Judson (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 364
Mendenhall (2004)
Dermatofibrosarcoma protuberans.Cancer, 101
J. Saab, I. Rosenthal, Lu Wang, K. Busam, K. Nehal, M. Dickson, M. Hameed, T. Hollmann (2017)
Dermatofibrosarcoma Protuberans-Like Tumor With COL1A1 Copy Number Gain in the Absence of t(17;22).The American Journal of Dermatopathology
Vincent Criscione, M. Weinstock (2007)
Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002.Journal of the American Academy of Dermatology, 56 6
S. Stacchiotti, M. Pantaleo, T. Negri, A. Astolfi, M. Tazzari, G. Dagrada, M. Urbini, V. Indio, R. Maestro, A. Gronchi, M. Fiore, A. Tos, E. Conca, E. Palassini, B. Vincenzi, F. Grosso, S. Pilotti, C. Castelli, P. Casali (2015)
Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)Clinical Cancer Research, 22
A. Hochhaus, S. O’Brien, F. Guilhot, B. Druker, S. Branford, L. Foroni, J. Goldman, M. Müller, J. Radich, M. Rudoltz, M. Mone, I. Gathmann, T. Hughes, R. Larson (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia, 23
B. Rubin, S. Schuetze, J. Eary, T. Norwood, S. Mirza, E. Conrad, J. Bruckner (2002)
Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 17
P. Rutkowski, A. Klimczak, I. Ługowska, B. Jagielska, M. Wągrodzki, M. Debiec-Rychter, Barbara Pienkowska-Grela, Tomasz Świtaj (2017)
Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 43 6
(2005)
Estimating the mean and variance from the median, range, and the size of a sample.
Á. Acosta, C. Vélez (2019)
Dermatofibrosarcoma ProtuberansCurrent Treatment Options in Oncology, 18
M. Zago (1996)
[Genes, chromosomes and cancer].Revista da Associacao Medica Brasileira, 42 4
M. Simon, F. Pedeutour, N. Sirvent, J. Grosgeorge, F. Minoletti, J. Coindre, M. Terrier-Lacombe, N. Mandahl, R. Craver, N. Blin, G. Sozzi, C. Turc‐Carel, K. O'Brien, D. Kedra, I. Fransson, C. Guilbaud, J. Dumanski (1997)
Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastomaNature Genetics, 15
G. Lowe, Oluwakemi Onajin, C. Baum, C. Otley, C. Arpey, R. Roenigk, J. Brewer (2017)
A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic ExperienceDermatologic Surgery, 43
T. Freedman, H. Lynch, S. Lemon, S. Tinley, J. Lynch, P. Watson (1997)
Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians
S. Bashir, M. Tariq, H. Aslam, Abdul Hashmi, B. Malik, Akhtar Amin, Sidra Mumtaz (2015)
Orbital dermatofibrosarcoma protuberans with intracranial extension preceded by recurrent leiomyoma of the orbit: a case reportJournal of Medical Case Reports, 9
Wang (2015)
Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.Medicine (Baltimore), 94
S. Ugurel, J. Becker (2017)
Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?The Journal of investigative dermatology, 137 2
T. Mentzel, A. Beham, D. Katenkamp, A. Tos, C. Fletcher (1998)
Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.The American journal of surgical pathology, 22 5
Lars Jørgensen, A. Paludan-Müller, D. Laursen, J. Savović, I. Boutron, J. Sterne, J. Higgins, A. Hrõbjartsson (2016)
Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviewsSystematic Reviews, 5
P. Saiag, J. Grob, C. Lebbé, J. Malvehy, V. Marmol, H. Pehamberger, K. Peris, A. Stratigos, Mark Middelton, Lars Basholt, A. Testori, C. Garbe (2015)
Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.European journal of cancer, 51 17
G. McArthur, G. Demetri, A. Oosterom, M. Heinrich, M. Debiec-Rychter, C. Corless, Z. Nikolova, S. Dimitrijević, J. Fletcher (2005)
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 4
P. Rutkowski, M. Glabbeke, C. Rankin, W. Ruka, B. Rubin, M. Debiec-Rychter, A. Lazar, H. Gelderblom, R. Sciot, D. Lopez-Terrada, P. Hohenberger, A. Oosterom, S. Schuetze (2010)
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
J. Ransohoff, B. Kwong (2017)
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.Clinical lymphoma, myeloma & leukemia, 17 12
Sirvent (2003)
Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment.Genes Chromosomes Cancer, 37
This systematic review evaluates the use of imatinib to treat locally advanced or metastatic dermatofibrosarcoma protuberans.
JAMA Dermatology – American Medical Association
Published: Mar 2, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.